Teva Pharmaceutical Industries Limited (NYSE:TEVA) Shares Sold by Migdal Insurance & Financial Holdings Ltd.

Migdal Insurance & Financial Holdings Ltd. lessened its holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 12.5% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 25,466,010 shares of the company’s stock after selling 3,652,200 shares during the quarter. Teva Pharmaceutical Industries accounts for about 7.4% of Migdal Insurance & Financial Holdings Ltd.’s holdings, making the stock its biggest position. Migdal Insurance & Financial Holdings Ltd.’s holdings in Teva Pharmaceutical Industries were worth $458,896,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. BI Asset Management Fondsmaeglerselskab A S acquired a new position in shares of Teva Pharmaceutical Industries during the 1st quarter worth $93,000. SG Americas Securities LLC grew its position in Teva Pharmaceutical Industries by 12.0% during the first quarter. SG Americas Securities LLC now owns 610,407 shares of the company’s stock worth $8,613,000 after buying an additional 65,529 shares during the period. Oppenheimer & Co. Inc. increased its holdings in Teva Pharmaceutical Industries by 9.6% in the first quarter. Oppenheimer & Co. Inc. now owns 13,522 shares of the company’s stock valued at $191,000 after buying an additional 1,180 shares in the last quarter. Sei Investments Co. increased its holdings in Teva Pharmaceutical Industries by 0.9% in the first quarter. Sei Investments Co. now owns 457,322 shares of the company’s stock valued at $6,453,000 after buying an additional 4,000 shares in the last quarter. Finally, Headlands Technologies LLC lifted its position in shares of Teva Pharmaceutical Industries by 339.4% during the 1st quarter. Headlands Technologies LLC now owns 15,206 shares of the company’s stock valued at $215,000 after acquiring an additional 11,745 shares during the period. Institutional investors and hedge funds own 54.05% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on TEVA. JPMorgan Chase & Co. upped their price target on Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the stock a “neutral” rating in a report on Monday, October 21st. UBS Group upped their target price on Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the company a “buy” rating in a report on Tuesday, September 3rd. Barclays lifted their price target on Teva Pharmaceutical Industries from $22.00 to $25.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 23rd. Finally, StockNews.com raised shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research note on Thursday, October 17th. Two equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $19.67.

Teva Pharmaceutical Industries Trading Down 2.2 %

Teva Pharmaceutical Industries stock opened at $17.11 on Friday. The stock has a 50-day moving average price of $17.94 and a 200 day moving average price of $17.12. Teva Pharmaceutical Industries Limited has a 52 week low of $8.55 and a 52 week high of $19.31. The company has a current ratio of 0.89, a quick ratio of 0.59 and a debt-to-equity ratio of 2.57.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings results on Wednesday, November 6th. The company reported $0.67 EPS for the quarter, topping analysts’ consensus estimates of $0.63 by $0.04. The business had revenue of $4.33 billion during the quarter, compared to the consensus estimate of $4.08 billion. Teva Pharmaceutical Industries had a negative net margin of 5.73% and a positive return on equity of 42.92%. On average, analysts expect that Teva Pharmaceutical Industries Limited will post 2.34 earnings per share for the current fiscal year.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.